Pipeline
We are developing differentiated peptide candidates to address unmet medical needs across therapeutic areas.
PARTNERS
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
-
Petrelintide
amylin analog
- Phase 2
-
Dapiglutide
GLP-1/GLP-2 receptor dual agonist
- Phase 1
-
Survodutide
glucagon/GLP-1 receptor dual agonist
-
PARTNERS
- Phase 3
-
ZP6590
GIP receptor agonist
- Preclinical
Congenital Hyperinsulinism
-
Dasiglucagon: Continuous infusion
glucagon analog
- Registration
Short Bowel Syndrome
-
Glepaglutide
GLP-2 analog
- Phase 3
Latest scientific publications
All Scientific publications-
Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-acting Amylin Analog
-
Dapiglutide is a dual agonist on human GLP-1- and GLP-2-receptors with a biased and prolonged signaling profile at the GLP-1R
-
Petrelintide (ZP8396) selectively reduces intake of high fat diet in DIO rats
-
Petrelintide (ZP8396) significantly reduces fat mass while preserving lean mass in DIO rats
We are targeting a number of important therapeutic areas of high unmet need with our robust pipeline of differentiated candidates.
David Kendall
Chief Medical Officer, Zealand Pharma
